Skip to main content

Table 2 Clinical variables (median, 25 and 75 percentile, mean ± SD at baseline, after 3 and 6 months, differences and statistical analysis

From: Adjunctive use of essential oils following scaling and root planing –a randomized clinical trial

N test group  =  23
N control group  =  23
Baseline 3 months 6 months Difference t0-t3 Difference t0-t6
BoP (%)
   Test
   Control
17.0 (13.0, 19.0) ***
16.0 (13.0, 19.0) ***
6.0 (4.0, 9.0) *** ††
9.0 (5.0, 12.0) ***
12.0 (9.0, 14.0) ***
11.0 (8.0, 17.0) ***
10.0 (8.0, 12.0) *** †
9.0 (6.0, 11.0) ***
5.0 (3.0, 8.0) ***
4.0 (2.0, 7.0) ***
   Test
   Control
16.5 ± 4.0
16.7 ± 5.5
6.2 ± 3.0
8.7 ± 3.7
11.5 ± 4.9
13.0 ± 6.7
10.3 ± 3.1
8.0 ± 4.0
5.0 ± 4.0
3.7 ± 5.6
SBI (%)
   Test group
   Control group
18.0 (14.0, 23.0) ***
16.0 (14.0, 21.0) ***
12.0 (8.0, 15.0) ***
11.0 (7.0, 15.0) ***
13.0 (11.0, 18.0) ***
13.0 (11.0, 15.0) ***
7.0 (4.0, 11.0) ***
8.0 (4.0, 12.0) ***
4.0 (0.0, 8.0) **
4.0 (3.0, 8.0) **
   Test
   Control
18.7 ± 6.5
18.1 ± 5.6
11.8 ± 4.4
10.3 ± 4.3
13.4 ± 5.2
13.4 ± 3.8
6.8 ± 5.2
7.8 ± 5.4
5.2 ± 5.7
4.7 ± 5.9
Mean PD (mm)
   Test
   Control
3.3 (3.1, 3.6) ***
3.2 (3.1, 3.5) ***
2.1 (2.0, 2.2) *** ††
2.2 (2.0, 2.5) ***
2.2 (2.0, 2.3) *** ††
2.3 (2.1, 2.5) ***
1.2 (0.8, 1.2) *** †
1.0 (0.9, 1.5) ***
1.1 (0.8, 1.2) ***
1.0 (0.8, 1.5) ***
   Test
   Control
3.3 ± 0.4
3.3 ± 0.3
2.1 ± 0.3
2.3 ± 0.2
2.2 ± 0.2
2.3 ± 0.3
1.2 ± 0.3
1.0 ± 0.3
1.1 ± 0.3
1.0 ± 0.3
Mean AL (mm)
   Test group
   Control group
3.5 (3.3, 3.7) ***
3.5 (3.3, 3.7) ***
2.5 (2.4, 2.6) *** ††
2.8 (2.5, 2.9) ***
2.6 (2.5, 2.7) *** ††
2.8 (2.7, 3.0) ***
0.9 (0.8, 1.1) *** †††
0.7 (0.6, 0.8) ***
0.9 (0.7, 1.0) *** †††
0.6 (0.5, 0.7) ***
   Test
   Control
3.5 ± 0.2
3.4 ± 0.3
2.5 ± 0.3
2.7 ± 0.3
2.6 ± 0.2
2.8 ± 0.3
1.0 ± 0.3
0.7 ± 0.2
0.9 ± 0.2
0.6 ± 0.2
Sites PD > 5 mm (n)
   Test
   Control
18.0 (13.0,27.0)
19.0 (9.0, 25.0)
0.0 (0.0, 2.0)
1.0 (0.0, 5.0)
0.0 (0.0, 2.0)
2.0 (0.0, 6.0)
17.0 (13.0, 26.0)
17.0 (8.0, 22.0)
18.0 (13.0, 25.0)
16.0 (7.0, 22.0)
   Test
   Control
18.7 ± 10.3
19.4 ± 13.0
1.1 ± 1.7
2.7 ± 3.3
1.3 ± 2.2
3.4 ± 4.2
17.6 ± 9.2
16.7 ± 10.2
17.4 ± 8.7
16.0 ± 9.9
Mean sites PD  >  5 mm (n)
   Test
   Control
5.3 (5.0, 5.5)
5.3 (5.0, 5.5)
3.0 (2.8, 3.3)
3,0 (2.8, 3.3)
3.0 (2.8, 3.5)
3.0 (2.8, 3.3)
2.5 (2.3, 2.5)
2.3 (2.0, 2.5)
2.3 (2.0, 2.5)
2.3 (2.0, 2.3)
   Test
   Control
5.3 ± 0.4
5.3 ± 0.4
3.0 ± 0.4
3.0 ± 0.3
3.1 ± 0.4
3.1 ± 0.3
2.3 ± 0.2
2.3 ± 0.3
2.2 ± 0.3
2.2 ± 0.4
Sites AL > 5 mm (n)
   Test
   Control
21.0 (14.0, 31.0)
21.0 (12.0, 27.0)
2.0 (0.0, 3.0)
2.0 (0.0, 6.0)
1.0 (0.0, 3.0)
3.0 (0.0, 8.0)
21.0 (14.0, 27.0)
16.0 (12.0, 24.0)
21.0 (14.0, 27.0)
16.0 (9.0, 23.0)
Test Control 21.3 ± 11.5
22.3 ± 14.7
2.1 ± 3.3
3.4 ± 4.2
2.4 ± 3.7
4.3 ± 4.4
19.2 ± 9.5
18.9 ± 11.7
18.9 ± 9.1
18.0 ± 11.7
Mean sites AL > 5 mm (n)
   Test
   Control
4.0 (4.0, 4.3)
4.0 (4.0, 4.3)
2.8 (2.8, 3.0)
3.0 (2.8, 3.0)
3.0 (3.0, 3.0)
3.0 (3.0, 3.3)
1.3 (1.3, 1.5)
1.3 (1.0, 1.5)
1.0 (1.0, 1.3)
1.0 (0.8, 1.3)
   Test
   Control
4.2 ± 0.3
4.1 ± 0.2
2.9 ± 0.2
2.9 ± 0.3
3.1 ± 0.2
3.1 ± 0.2
1.3 ± 0.2
1.2 ± 0.3
1.1 ± 0.3
1.0 ± 0.2
  1. Wilcoxon signed rank test: significant longitudinal changes t3 - t0, t6 - t0 within each group
  2. ** 0.01  <  p  <  0.05, *** p  <  0.001
  3. Mann Whitney test between the groups (test-control): † 0.05  <  p  <  0.1, †† 0.01  <  p  <  0.05, †††    <  0.001
\